Sibionics and PharmaSens announce exploration of integrating continuous glucose sensing with automated insulin delivery at EASD 2026
Executive summary: Sibionics and PharmaSens revealed at EASD 2026 that they are exploring a partnership to connect continuous glucose sensing with automated insulin delivery technology. Such a link could accelerate the availability of integrated glucose‑insulin systems, increasing competition for established players like Medtronic, Insulet and Tandem Diabetes.
Who is involved: Sibionics (sensor developer), PharmaSens (insulin delivery specialist), and the European Association for the Study of Diabetes (host of the conference).
Likely next: The companies may sign a joint development agreement by the end of 2026, followed by feasibility studies and a regulatory submission (FDA/CE) targeted for 2027.
At the European Association for the Study of Diabetes conference in Milan, Sibionics showcased its "See More, Act Earlier" vision, which links advanced continuous sensing to future diabetes care solutions. The company said it is discussing with PharmaSens how to combine Sibionics’ sensing platform with PharmaSens’ insulin delivery expertise to move toward a more automated system. No financial terms or timelines were disclosed in the release, but the collaboration signals a potential new entrant in the automated insulin delivery market.
What's next — scenarios
Base: exploratory talks continue, no deal yet (50%)
No immediate product impact; market watchers await further updates.
- No joint development agreement announced by 31 Dec 2026
- No public update on feasibility study by Q2 2027
Upside: agreement signed and pilot study launched (30%)
Early feasibility data expected mid‑2027, potentially accelerating a CE‑marked automated insulin delivery system by 2028.
- Joint development agreement signed by 31 Dec 2026
- First patient enrollment in a pilot study by 30 Jun 2027
Downside: talks stall due to technical or strategic mismatch (20%)
Both firms pursue independent routes, delaying any integrated offering and preserving the status quo for incumbent AID vendors.
- No agreement announced by 31 Mar 2027
- Public statement from either side ending exploration by 30 Jun 2027
What to watch
- Announcement of a joint development agreement (expected by end‑2026)
- Submission of a 510(k) or CE marking application for an integrated sensor‑pump system (expected mid‑2027)
- Presentation of feasibility or pilot study results at EASD 2027
- Any regulatory feedback from FDA or EU notified bodies on the combined technology
Timeline
- — SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026 (PR Newswire)
Analysis — what this means
Likely next events
- Joint development agreement targeted for signing by 31 Dec 2026
- First feasibility study patient enrollment planned for Q2 2027
- Regulatory submission (FDA 510(k) or CE mark) anticipated by Q3 2027
Sectors affected
- Continuous glucose monitoring (CGM)
- Insulin pump technology
- Automated insulin delivery (AID) systems
- Diabetes care devices
Regulatory implications
- Need to satisfy EU MDR requirements for combined sensor‑pump products (CE marking)
- FDA 510(k) clearance will require demonstrating safety and effectiveness of the integrated algorithm
- Compliance with ISO 14708‑3 for active implantable medical devices may apply if the system includes implantable components
Historical parallels
- Dexcom and Tandem Diabetes announced integrated CGM‑pump partnership in 2020, leading to the t:slim X2 with Dexcom G6
- Medtronic’s MiniMed 670G hybrid closed‑loop system launched in 2016, establishing the first widely adopted AID
Key entities
Sources
- SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026 — PR Newswire
Related cases
- Hansoh Pharma’s dual‑biased GLP‑1/GIP agonist olatorepatide achieves 19.3% weight loss at week 48, signalling a new contender in the obesity drug market
- Sinocare launches integrated chronic disease management solutions at EASD 2026, signaling expansion in digital health for diabetes care
- Eli Lilly accelerates cardiometabolic leadership with pivotal new clinical data presentation at EASD 2026
- Ascletis claims its oral ASC36_35 FDC outperforms eloralintide/tirzepatide combo in preclinical obesity model, positioning it as a potential next‑generation weight‑loss therapy